{"generic":"Olodaterol","drugs":["Olodaterol","Striverdi Respimat"],"mono":{"0":{"id":"931014-s-0","title":"Generic Names","mono":"Olodaterol"},"1":{"id":"931014-s-1","title":"Dosing and Indications","sub":[{"id":"931014-s-1-4","title":"Adult Dosing","mono":"<b>Chronic obstructive pulmonary disease:<\/b> 2 ORAL inhalations (5 mcg) once daily at the same time each day "},{"id":"931014-s-1-5","title":"Pediatric Dosing","mono":"safety and efficacy not established in pediatric patients "},{"id":"931014-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>Renal impairment:<\/b> No dose adjustment necessary<\/li><li><b>Mild to moderate hepatic impairment:<\/b> No dose adjustment necessary<\/li><li><b>Severe hepatic impairment:<\/b> No dosing information available<\/li><li><b>Geriatric:<\/b> No dose adjustment necessary<\/li><\/ul>"},{"id":"931014-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Chronic obstructive pulmonary disease<br\/>"}]},"2":{"id":"931014-s-2","title":"Black Box Warning","mono":"<b>Inhalation (Solution)<\/b><br\/>Salmeterol, a long-acting beta(2)-adrenergic agonists (LABA), has been shown to increase the risk of asthma-related death. This is considered a LABA class effect, and olodaterol is not indicated for asthma treatment.<br\/>"},"3":{"id":"931014-s-3","title":"Contraindications\/Warnings","sub":[{"id":"931014-s-3-9","title":"Contraindications","mono":"asthma <br\/>"},{"id":"931014-s-3-10","title":"Precautions","mono":"<ul><li>Black Box Warning:<\/li><li>-- increased risk of asthma-related death with use of long-acting beta(2)-adrenergic agonists (off-label use)<\/li><li>Cardiovascular:<\/li><li>-- clinically significant cardiovascular effects may occur (eg, increases in blood pressure or pulse rate, QT-interval prolongation, ST segment depression, T wave flattening), with greater risk among patients with coronary insufficiency, QT-interval prolongation or other cardiac arrhythmias, hypertrophic cardiomyopathy, or hypertension; discontinuation may be required<\/li><li>Endocrine Metabolic Effects:<\/li><li>-- use cautiously in patients with thyrotoxicosis<\/li><li>-- may induce significant hypokalemia, which can progress to cardiac arrhythmia; increased risk among patients with hypoxia<\/li><li>-- clinically significant changes in blood glucose may occasionally occur<\/li><li>Immunologic Effects:<\/li><li>-- hypersensitivity reactions, including angioedema, have been reported; immediately discontinue if condition occurs<\/li><li>Neurologic:<\/li><li>-- use cautiously in patients with convulsive disorders<\/li><li>Respiratory Effects:<\/li><li>-- not for treatment of acute symptoms (ie, bronchospasm)<\/li><li>-- life-threatening paradoxical bronchospasm may occur; immediately discontinue if condition develops<\/li><li>Other:<\/li><li>-- loss of efficacy warrants immediate clinical evaluation, as this may be a marker of disease deterioration; do not increase dose<\/li><li>-- avoid higher or more frequent dosing than recommended due to increased risk of cardiovascular effects or death<\/li><li>-- use cautiously in patients with high sympathomimetic amine sensitivity<\/li><li>Concomitant Use:<\/li><li>-- avoid use with other long-acting beta(2) agonists<\/li><\/ul>"},{"id":"931014-s-3-11","title":"Pregnancy Category","mono":"<ul><li>C (FDA)<\/li><li>B3 (AUS)<\/li><\/ul>"},{"id":"931014-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"931014-s-4","title":"Drug Interactions","sub":{"1":{"id":"931014-s-4-14","title":"Major","mono":"<ul><li>Acebutolol (theoretical)<\/li><li>Amineptine (theoretical)<\/li><li>Amitriptyline (theoretical)<\/li><li>Amitriptylinoxide (theoretical)<\/li><li>Amoxapine (theoretical)<\/li><li>Atenolol (theoretical)<\/li><li>Befunolol (theoretical)<\/li><li>Betaxolol (theoretical)<\/li><li>Bevantolol (theoretical)<\/li><li>Bisoprolol (theoretical)<\/li><li>Bopindolol (theoretical)<\/li><li>Carteolol (theoretical)<\/li><li>Carvedilol (theoretical)<\/li><li>Celiprolol (theoretical)<\/li><li>Clomipramine (theoretical)<\/li><li>Desipramine (theoretical)<\/li><li>Dibenzepin (theoretical)<\/li><li>Doxepin (theoretical)<\/li><li>Esmolol (theoretical)<\/li><li>Furazolidone (probable)<\/li><li>Imipramine (theoretical)<\/li><li>Iproniazid (probable)<\/li><li>Isocarboxazid (probable)<\/li><li>Labetalol (theoretical)<\/li><li>Landiolol (theoretical)<\/li><li>Levobunolol (theoretical)<\/li><li>Linezolid (probable)<\/li><li>Lofepramine (theoretical)<\/li><li>Melitracen (theoretical)<\/li><li>Mepindolol (theoretical)<\/li><li>Methylene Blue (probable)<\/li><li>Metipranolol (theoretical)<\/li><li>Metoprolol (theoretical)<\/li><li>Moclobemide (probable)<\/li><li>Nadolol (theoretical)<\/li><li>Nebivolol (theoretical)<\/li><li>Nipradilol (theoretical)<\/li><li>Nortriptyline (theoretical)<\/li><li>Opipramol (theoretical)<\/li><li>Oxprenolol (theoretical)<\/li><li>Pargyline (probable)<\/li><li>Penbutolol (theoretical)<\/li><li>Phenelzine (probable)<\/li><li>Pindolol (theoretical)<\/li><li>Procarbazine (probable)<\/li><li>Propranolol (theoretical)<\/li><li>Protriptyline (theoretical)<\/li><li>Rasagiline (probable)<\/li><li>Selegiline (probable)<\/li><li>Sotalol (theoretical)<\/li><li>Talinolol (theoretical)<\/li><li>Tertatolol (theoretical)<\/li><li>Tianeptine (theoretical)<\/li><li>Timolol (theoretical)<\/li><li>Tranylcypromine (probable)<\/li><li>Trimipramine (theoretical)<\/li><\/ul>"}}},"5":{"id":"931014-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><br\/><b>Respiratory:<\/b>Nasopharyngitis (11.3%), Upper respiratory infection (8.2%)<br\/><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Cardiovascular system problem, Electrocardiogram abnormal<\/li><li><b>Endocrine metabolic:<\/b>Hypokalemia<\/li><li><b>Immunologic:<\/b>Hypersensitivity reaction<\/li><li><b>Respiratory:<\/b>Paradoxical bronchospasm, Pneumonia (greater than 2%)<\/li><\/ul>"},"6":{"id":"931014-s-6","title":"Drug Name Info","sub":{"0":{"id":"931014-s-6-17","title":"US Trade Names","mono":"Striverdi Respimat<br\/>"},"2":{"id":"931014-s-6-19","title":"Class","mono":"<ul><li>Beta-2 Adrenergic Agonist<\/li><li>Bronchodilator<\/li><\/ul>"},"3":{"id":"931014-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"931014-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"931014-s-7","title":"Mechanism Of Action","mono":"Olodaterol is a long-acting beta-2 agonist (LABA) that binds to beta-2 receptors, which are found in airways and other tissues such as cardiac muscle. Beta-2 receptor stimulation triggers intracellular adenyl cyclase, which stimulates cyclic-3',5' adenosine monophosphate (cAMP) synthesis. Increased cAMP relaxes smooth muscle cells in airways causing bronchodilation.<br\/>"},"8":{"id":"931014-s-8","title":"Pharmacokinetics","sub":[{"id":"931014-s-8-23","title":"Absorption","mono":"<ul><li>Tmax, inhalation: within 10 to 20 minutes<\/li><li>Bioavailability, inhalation: 30%<\/li><\/ul>"},{"id":"931014-s-8-24","title":"Distribution","mono":"<ul><li>Protein binding: 60%<\/li><li>Vd: 1110 L<\/li><\/ul>"},{"id":"931014-s-8-25","title":"Metabolism","mono":"<ul><li>Hepatic: Extensive<\/li><li>Unconjugated demethylated olodaterol: Active<\/li><li>Olodaterol glucuronides: Inactive<\/li><li>Substrate of CYP2C9, CYP2C8, UGT2B7, UGT1A1, UGT1A7, and UGT1A9<\/li><\/ul>"},{"id":"931014-s-8-26","title":"Excretion","mono":"<ul><li>Renal: 38%<\/li><li>Fecal: 53%<\/li><li>Renal clearance: 173 mL\/min<\/li><li>Total body clearance: 872 mL\/min<\/li><\/ul>"},{"id":"931014-s-8-27","title":"Elimination Half Life","mono":"45 hours <br\/>"}]},"9":{"id":"931014-s-9","title":"Administration","mono":"<b>Inhalation, oral<\/b><br\/><ul><li>prime inhaler before first use by actuating until aerosol cloud is visible, then repeat 3 more times<\/li><li>if inhaler not used for more than 3 days, actuate once before use to reprime<\/li><li>If inhaler not used for more than 21 days, repeat initial priming process<\/li><li>exhale slowly and fully, then close lips around mouthpiece; do not cover air vents<\/li><li>press dose release button while slowly and deeply inhaling through mouth; breath in for as long as possible, then hold breath for 10 seconds or as long as comfortable<\/li><li>discard inhaler 3 months after first use or when locking mechanism activates, whichever occurs first<\/li><\/ul>"},"10":{"id":"931014-s-10","title":"Monitoring","mono":"<ul><li>improvement or maintenance of respiratory function in patients with COPD may indicate efficacy<\/li><li>respiratory function, in patients with signs or symptoms suggestive of deterioration of disease<\/li><\/ul>"},"11":{"id":"931014-s-11","title":"How Supplied","mono":"<b>Striverdi Respimat<\/b><br\/>Inhalation Spray: 2.5 MCG\/Actuation<br\/>"},"13":{"id":"931014-s-13","title":"Clinical Teaching","mono":"<ul><li>Advise patient that drug should not be used for COPD exacerbations or acute asthma symptoms.<\/li><li>Warn patient to report symptoms of paradoxical bronchospasm, worsening COPD, or decreased efficacy of drug.<\/li><li>Encourage patient to report cardiovascular symptoms such as elevated pulse rate or blood pressure.<\/li><li>Side effects may include bronchitis, cough, nasopharyngitis, upper respiratory tract infection, dizziness, back pain, arthralgia, or diarrhea.<\/li><li>Advise patient on proper inhalation technique.<\/li><li>Warn patient not to exceed the recommended dose.<\/li><li>Tell patient to avoid using other long-acting beta-2 agonists with drug.<\/li><\/ul>"}}}